Related Experiment Videos
[Parathyroid hormone in osteoporosis].
1Service de Rhumatologie du Pr. A. Kahan, Hôpital Cochin, AP-HP, Paris. Catherine.Cormier@cch.ap-hop-paris.fr
Presse Medicale (Paris, France : 1983)
|March 22, 2006
Summary
Primary hyperparathyroidism causes osteoporosis through continuous parathyroid hormone (PTH) secretion. Intermittent PTH treatment, however, stimulates bone formation, offering a therapeutic approach for osteoporosis.
Area of Science:
- Endocrinology
- Bone Biology
- Metabolic Diseases
Context:
- Primary hyperparathyroidism (PHP) is characterized by continuous parathyroid hormone (PTH) secretion.
- This continuous PTH secretion contributes to the development of osteoporosis.
- Bone damage in PHP predominantly impacts cortical bone, particularly the proximal radius and femur.
Purpose:
- To clarify the role of parathyroid hormone in osteoporosis.
- To highlight the diagnostic utility of intact PTH assays for hyperparathyroidism.
- To explore the potential of intermittent PTH administration as an osteoporosis treatment.
Summary:
- Continuous PTH secretion in PHP leads to bone loss, primarily affecting cortical bone.
- The intact PTH assay is crucial for diagnosing hyperparparathyroidism.
- Intermittent PTH administration stimulates bone formation by favoring osteoblastic activity over osteoclastic activity.
Impact:
- Understanding the dual role of PTH in bone metabolism.
- Improved diagnosis and management of hyperparathyroidism.
- Potential for novel therapeutic strategies for osteoporosis using intermittent PTH.